Understanding how JAG1 affects immune responses in pancreatic cancer
Mechanisms of JAG1-mediated immune suppression in the pancreatic cancer microenvironment
This study is looking at how a protein called JAG1 affects the immune system in people with pancreatic cancer, with the goal of finding ways to improve treatments that help the body fight the cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Methodist Hospital Research Institute NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-10995190 on NIH RePORTER |
What this research studies
This research investigates the role of JAG1, a protein involved in cell signaling, in the immune suppression seen in pancreatic cancer. The study aims to uncover how JAG1 influences the development and function of dendritic cells, which are crucial for activating the immune response against tumors. By targeting JAG1, the researchers hope to enhance the effectiveness of immunotherapy in patients with pancreatic cancer, who often experience poor outcomes due to a suppressive tumor environment. The approach includes analyzing the interactions between JAG1 and immune cells to identify potential therapeutic strategies.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with pancreatic cancer who are seeking new treatment options.
Not a fit: Patients with early-stage pancreatic cancer or those who do not have a significant immune response may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved immunotherapy options for pancreatic cancer patients, potentially enhancing their survival rates.
How similar studies have performed: Previous studies have shown that targeting immune pathways can improve treatment outcomes in other cancers, suggesting potential for success in this novel approach.
Where this research is happening
Houston, United States
- Methodist Hospital Research Institute — Houston, United States (Active)
Researchers
- Principal investigator: Zhou, Lan — Methodist Hospital Research Institute
- Study coordinator: Zhou, Lan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.